[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-injuries\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-injuries":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,60,93,107,130,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":5},"100053384","phase-3-bevacizumab-versus-corticosteroids-as-first-line-treatment-in-patients-with-symptomatic-cerebral-radiation-necrosis-after-radiation-for-high-grade-glioma-or-brain-metastases-100053384",false,"NCT06888817","Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases","Bevacizumab for the Treatment of Cerebral RAdiation Induced NecrosiS (BRAINS) Study: a Multicenter, Open-label, Randomized Clinical Trial to Assess the Clinical Efficacy and Cost-effectiveness of Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases","BRAINS","Inclusion Criteria:\n\nInclusion all patients (both HGG and BM):\n\n1. Age ≥ 18 years old\n2. First episode of sCRN ≥ 3 months after completion of focal (re-)irradiation, as determined by the local Multidisciplinary Neuro-Oncology Board. A clear working diagnosis of CRN without evidence of a combination with tumour progression is required\n3. KPS score ≤ 90 and either (a) a minimum loss of two points in at least one domain of the Neurologic Assessment in Neuro-Oncology (NANO) scale as compared to the maximum score of that domain due to sCRN, or (b) a headache attributable to sCRN with an average intensity ≥5\u002F10 on the NRS, persisting for ≥10 consecutive days, with inadequate relief despite an adequate trial of paracetamol and\u002For an NSAID unless these medications are contra-indicated or not tolerated\n4. Maximum daily dexamethasone use of 1 mg\u002Fday for the 8 weeks preceding randomization\n\n   1. Dexamethasone may have been prescribed for various indications, except for managing (ongoing) cerebral edema\n   2. Higher doses of dexamethasone are permitted 3 weeks immediately preceding randomization if used specifically for the treatment of sCRN\n5. Able to understand the patient information, online tests and questionnaires\n6. Written informed consent\n\nInclusion BM:\n\n1\\. BM of solid tumour, including all primary tumour types\n\nInclusion HGG:\n\n1\\. A confirmed histological diagnosis of high-grade diffuse glioma according to WHO 2021 criteria, including: astrocytoma, IDH-mutant, grade 3-4; astrocytoma, IDH-wildtype (sybtype molecular glioblastoma); oligodendroglioma, 1p\u002F19q codeleted, grade 3; diffuse glioma, NEC, grade 3-4; or glioblastoma, IDH-wildtype, grade 4\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study, both for the BM and HGG group:\n\n1. Prior treatment with bevacizumab \\\u003C6 months before diagnosis of sCRN\n2. Life expectancy \\\u003C3 months\n3. Impending radiological or clinical signs of brain herniation necessitating immediate decompressive surgery\n4. Any comorbidity or condition that prevents safe administration of the studied medication, determined by the treating physician, including but not limited to:\n\n   1. Intolerance for murine proteins\n   2. Hypersensitivity or allergy to the active substance or to any of the excipients of bevacizumab or dexamethasone\n   3. Nephrotic syndrome or abnormal renal function\n\n      o Calculated (Cockcroft-Gault) or measured creatinine clearance \\\u003C30 mL\u002Fmin; urine dipstick for proteinuria ≥ 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein\u002F24 hr.\n   4. Clinical significant cardiovascular disease\n\n      * Uncontrolled hypertension (systolic BP \\>150mmHg and\u002For diastolic \\>100mmHg) despite the use of ≥ 3 antihypertensive drugs\n      * Previous hypertensive crisis, hypertensive encephalopathy or previous reversible posterior leukoencephalopathy syndrome (RPLS)\n      * Non tumour related vascular event (e.g. cerebral or cardiac ischemia\u002Fbleeding (including transient ischemic attack, cerebral ischemia, unstable angina or angina requiring intervention, myocardial infarction), peripheral arterial thrombus, peripheral artery disease, deep venous thrombosis, lung embolism) \\\u003C 6 months\n      * History of aortic aneurysm or dissection\n      * Congestive heart failure NYHA II-IV\n   5. History of gastro-intestinal fistula, perforation or abscess \\\u003C 6 months\n   6. History of bleeding\n\n      * Relevant pulmonary hemorrhage\u002F hemoptysis \\\u003C 1 month or the presence of a pulmonary lesion with a high risk of bleeding (= central lung tumour and\u002For untreated squamous cell carcinoma) according to the treating physician\n      * Active gastrointestinal bleeding \\\u003C 6 months\n      * Evidence of recent intracranial hemorrhage on MRI brain \\\u003C3 months. Asymptomatic presence of hemosiderin depositions or punctate hemorrhage in the tumour do not serve as a ground for exclusion\n   7. Excess risk of bleeding\n\n      * History or evidence of inherited bleeding diathesis or significant coagulopathy with the risk of bleeding\n      * Decreased platelet count \\\u003C 75x109\u002FL\n   8. Risk of wound healing complications\n\n      * Significant non-healing wound, (peptic) ulcer or bone fracture\n      * Major surgical procedure (including open biopsy) or significant traumatic injury within 28 days prior to first study treatment or planned surgical procedure within the following next 28 days after planned study inclusion\n      * Minor surgical procedure, stereotactic\u002Fcore biopsy, fine needle aspiration within 7 days prior to first study treatment\n   9. High-dose radiotherapy to the mediastinum, abdomen, or lower pelvis; administration of bevacizumab should only be considered after prior consultation with a pulmonologist or oncologist\n   10. Pregnancy or lactation. Women of child bearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of HCG) within 7 days prior to randomization. WOCBP and female partners of male patients must comply with adequate contraception methods as requested by the study protocol\n   11. Evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the study treatment, affect patient compliance or place the patient at high risk for treatment-related complications according to the treating physician\n   12. Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another interventional study In case of uncertainty, consult the principal investigator of the study site.","ALL","18 Years",{"count":20,"type":21},408,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Cerebral radiation necrosis (CRN) is a severe complication of high-dose radiation for brain metastases (BM) or glioma, which can potentially cause significant neurologic symptoms leading to serious morbidity and impaired quality of life (QoL). The first-line therapy for symptomatic CRN (sCRN) is corticosteroids, primarily dexamethasone, which often leads to complications, refractory symptoms, and interference with anti-cancer treatment. Since 2017, bevacizumab, an antibody against Vascular Endothelial Growth Factor (VEGF), has been used in a second-line treatment setting for refractory sCRN. A small randomized clinical trial (RCT) has shown that bevacizumab significantly diminishes cerebral edema on MRI and decreases clinical symptoms of sCRN in irradiated glioma patients. Several non-randomized clinical studies demonstrated a beneficial radiological and clinical effect of bevacizumab in patients with sCRN after irradiation for BM. The optimal first-line treatment for sCRN is currently unknown. Effective and safe first-line treatment of sCRN will optimize the patient's well-being and health-related QoL. Furthermore, minimizing corticosteroid use will benefit the clinical treatment options and outcomes of concomitant or future anti-cancer treatment. This phase III multicenter, open-label, randomized clinical trial compares the clinical efficacy of first-line bevacizumab versus standard-of-care dexamethasone for sCRN in patients with high-grade glioma (HGG) or BM.",[27,28,29,30,31,32,33],"Radiation Necrosis","High Grade Glioma (III or IV)","Brain Metastasases","Radiation Toxicity","Radiation Effect","Radiation Injury","Radiation Injuries",[35,36,37,38,39,40,41,42,43,44,45,46,47],"Cerebral radiation necrosis","High Grade Glioma","Brain Metastases","Bevacizumab","Dexamethasone","Randomized Clinical Trial","First-line treatment","Anti-VEGF monocolonal antibody","Corticosteroids","Radiation induced necrosis","Radiation effects","Radiation injury","Radiation toxicity","RECRUITING","2026-07-09",{"date":51,"type":52},"2026-07-13","ACTUAL",{"date":54,"type":52},"2025-06-19",{"date":56,"type":21},"2030-07",{"name":58,"class":59},"The Netherlands Cancer Institute","OTHER",{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100635453","pseudomembrane-removal-for-post-rt-nasopharyngeal-necrosis-100635453","NCT07552883","Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis","Endoscopic Nasopharyngeal Pseudomembrane Removal for Prevention of Radiation-Induced Nasopharyngeal Necrosis After Re-irradiation in Recurrent Nasopharyngeal Carcinoma: A Single-Arm, Multicenter Interventional Study","EPoRN","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form.\n* Age between 18 and 80 years.\n* ECOG performance status ≤ 2.\n* Prior radical radiotherapy with total dose ≥ 66 Gy.\n* Imaging or histopathology confirmed local recurrence and\u002For retropharyngeal lymph node recurrence, with or without cervical lymph node recurrence.\n* Re-irradiation with single dose \\\u003C 2.3 Gy and total dose ≥ 50 Gy.\n* Presence of pseudomembrane reaction on nasopharyngeal mucosa during or after re-irradiation.\n* Expected survival \\> 1 year.\n* Induction chemotherapy, immunotherapy, concurrent chemotherapy, adjuvant chemotherapy, or radiotherapy alone are all permitted.\n\nExclusion Criteria:\n\n* History of other malignancies within the past 5 years, except cured non-melanoma skin cancer or carcinoma in situ of the cervix.\n* Severe uncontrolled systemic diseases (e.g., uncontrolled infection, severe cardiovascular disease, uncontrolled diabetes).\n* Pregnant or breastfeeding women.\n* Known allergy to any equipment or medication used during endoscopy.\n* Inability to tolerate endoscopic procedure due to anatomical or medical reasons.\n* Concurrent participation in another interventional clinical trial.\n* Any condition that, in the investigator's judgment, would interfere with study compliance or outcome assessment.","80 Years",{"count":70,"type":21},40,[72],"NA","This study aims to evaluate the effectiveness and safety of endoscopic nasopharyngeal pseudomembrane removal in reducing radiation-induced nasopharyngeal necrosis in patients with recurrent nasopharyngeal carcinoma who have received re-irradiation. This is a prospective, single-arm, multicenter interventional study. Participants with recurrent nasopharyngeal carcinoma who develop pseudomembrane reaction during or after re-irradiation will receive endoscopic pseudomembrane removal. Based on published literature, the 2-year incidence of radiation-induced nasopharyngeal necrosis after re-irradiation is approximately 40%. This study expects to reduce the incidence to 20%. The primary outcome measure is the 2-year incidence of nasopharyngeal necrosis after re-irradiation. Secondary outcome measures include: necrosis-free survival, overall survival, progression-free survival, local regional recurrence-free survival, distant metastasis-free survival, as well as safety and adverse events. A total of 40 participants will be enrolled from multiple hospitals in China.",[75,33,76],"Nasopharyngeal Carcinoma (NPC)","Necrosis",[78,79,80,81,82],"recurrent NPC","re-RT","radiation necrosis","pseudomembrane","endoscopy","NOT_YET_RECRUITING","2026-04-20",{"date":86,"type":52},"2026-04-27",{"date":88,"type":21},"2026-04-30",{"date":90,"type":21},"2031-04-30",{"name":92,"class":59},"Jiangxi Provincial Cancer Hospital",{"id":94,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":25,"conditions":98,"keywords":99,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":105,"locationsCount":106},"100584398","Inclusion Criteria:\n\nInclusion all patients (both HGG and BM):\n\n1. Age ≥ 18 years old\n2. First episode of sCRN ≥ 3 months after completion of focal (re-)irradiation, as determined by the local Multidisciplinary Neuro-Oncology Board. A clear working diagnosis of CRN without evidence of a combination with tumour progression is required\n3. KPS score ≤ 90 and a minimum loss of two points in at least one domain of the NANO scale as compared to the maximum score of at that domain due to sCRN\n4. Maximum daily dexamethasone use of 1 mg\u002Fday for the 8 weeks preceding randomization\n\n   1. Dexamethasone may have been prescribed for various indications, except for managing (ongoing) cerebral edema\n   2. Higher doses of dexamethasone are permitted during the week immediately preceding randomization if used specifically for the treatment of sCRN\n5. Able to understand the patient information, online tests and questionnaires\n6. Written informed consent\n\nInclusion BM:\n\n1\\. BM of solid tumour, including all primary tumour types\n\nInclusion HGG:\n\n1\\. A confirmed histological diagnosis of high-grade diffuse glioma according to WHO 2021 criteria, including: astrocytoma, IDH-mutant, grade 3-4; astrocytoma, IDH-wildtype (sybtype molecular glioblastoma); oligodendroglioma, 1p\u002F19q codeleted, grade 3; diffuse glioma, NEC, grade 3-4; or glioblastoma, IDH-wildtype, grade 4\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study, both for the BM and HGG group:\n\n1. Prior treatment with bevacizumab \\\u003C6 months before diagnosis of sCRN\n2. Life expectancy \\\u003C3 months\n3. Impending radiological or clinical signs of brain herniation necessitating immediate decompressive surgery\n4. Any comorbidity or condition that prevents safe administration of the studied medication, determined by the treating physician, including but not limited to:\n\n   1. Intolerance for murine proteins\n   2. Hypersensitivity or allergy to the active substance or to any of the excipients of bevacizumab or dexamethasone\n   3. Nephrotic syndrome or abnormal renal function\n\n      o Calculated (Cockcroft-Gault) or measured creatinine clearance \\\u003C30 mL\u002Fmin; urine dipstick for proteinuria ≥ 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein\u002F24 hr.\n   4. Clinical significant cardiovascular disease\n\n      * Uncontrolled hypertension (systolic BP \\>150mmHg and\u002For diastolic \\>100mmHg) despite the use of ≥ 3 antihypertensive drugs\n      * Previous hypertensive crisis, hypertensive encephalopathy or previous reversible posterior leukoencephalopathy syndrome (RPLS)\n      * Non tumour related vascular event (e.g. cerebral or cardiac ischemia\u002Fbleeding (including transient ischemic attack, cerebral ischemia, unstable angina or angina requiring intervention, myocardial infarction), peripheral arterial thrombus, peripheral artery disease, deep venous thrombosis, lung embolism) \\\u003C 6 months\n      * History of aortic aneurysm or dissection\n      * Congestive heart failure NYHA II-IV\n   5. History of gastro-intestinal fistula, perforation or abscess \\\u003C 6 months\n   6. History of bleeding\n\n      * Relevant pulmonary hemorrhage\u002F hemoptysis \\\u003C 1 month or the presence of a pulmonary lesion with a high risk of bleeding (= central lung tumour and\u002For untreated squamous cell carcinoma) according to the treating physician\n      * Active gastrointestinal bleeding \\\u003C 6 months\n      * Evidence of recent intracranial hemorrhage on MRI brain \\\u003C3 months. Asymptomatic presence of hemosiderin depositions or punctate hemorrhage in the tumour do not serve as a ground for exclusion\n   7. Excess risk of bleeding\n\n      * History or evidence of inherited bleeding diathesis or significant coagulopathy with the risk of bleeding\n      * Decreased platelet count \\\u003C 75x109\u002FL\n   8. Risk of wound healing complications\n\n      * Significant non-healing wound, (peptic) ulcer or bone fracture\n      * Major surgical procedure (including open biopsy) or significant traumatic injury within 28 days prior to first study treatment or planned surgical procedure within the following next 28 days after planned study inclusion\n      * Minor surgical procedure, stereotactic\u002Fcore biopsy, fine needle aspiration within 7 days prior to first study treatment\n   9. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hours urine collection and must demonstrate ≤ 1 g of protein\u002F24 hr.\n   10. Previous, current or planned high dose radiotherapy in the abdomen\n   11. Pregnancy or lactation. Women of child bearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of HCG) within 7 days prior to randomization. WOCBP and female partners of male patients must comply with adequate contraception methods as requested by the study protocol\n   12. Evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the study treatment, affect patient compliance or place the patient at high risk for treatment-related complications according to the treating physician\n   13. Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another interventional study In case of uncertainty, consult the principal investigator of the study site.",{"count":20,"type":21},[24],[27,28,29,30,31,32,33],[35,36,37,38,39,40,41,42,43,44,45,46,47],"2026-02-24",{"date":102,"type":52},"2026-02-25",{"date":54,"type":52},{"date":56,"type":21},{"name":58,"class":59},5,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100610746","early-phase-1-oral-5-strain-probiotic-for-gi-toxicity-mitigation-during-pelvic-radiation-100610746","NCT07231588","Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation","Feasibility of an Oral 5 Strain Probiotic (PGC) for GI Toxicity Mitigation During Pelvic Radiation","Inclusion Criteria:\n\n1. Patients must have histologically confirmed malignancy for which the standard of care treatment is at least 30 Gy of pelvic RT to the pelvic lymph nodes.\n\n   a. Eligible diagnoses include: i. Lower GI cancers (anal, rectal) ii. Gynecologic cancers (cervical, vulvar, vaginal, endometrial) iii. Prostate cancer with lymph node involvement\n2. Age ≥18 years.\n3. ECOG performance status ≤2 (or Karnofsky ≥60%, see Appendix A).\n4. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with inflammatory bowel disease (IBD - such as Crohn's or Ulcerative Colitis).\n2. Patients who are currently receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the PI.\n3. Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous, in the opinion of the Investigator.\n4. Patients with a prior or concurrent malignancy whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of the investigational regimen in the opinion of the Investigator.\n5. Patients who have received previous radiation therapy to the pelvis at any time.\n6. Patients who have not recovered from GI adverse events due to previous cancer therapy.\n7. Patients with colostomy or ileostomy.\n8. Pregnant women are excluded from this study because they cannot receive radiotherapy.\n9. Known inulin intolerance or allergies or hypersensitivity to any of the components of PGC, including:\n\n   1. Known hypersensitivity to \\>4 first-line antimicrobial therapies against Akkermansia muciniphila, Clostridium beijerinckii, Clostridium butyricum, Anaerobutyricum hallii: Penicillin, Piperacillin, Tetracycline, Amoxicillin, Ampicillin\n   2. Known hypersensitivity to \\>4 first-line antimicrobial therapies against Bifidobacterium infantis Bi-26TM: Gentamicin, Kanamycin, Streptomycin, Tetracycline, Erythromycin, Clindamycin, Ampicillin, Vancomycin\n10. Patients unable to swallow capsules.\n11. Absolute Neutrophil Count (ANC) \\\u003C 1500\u002FuL.",{"count":115,"type":21},20,[117],"EARLY_PHASE1","This research is to determine if an oral probiotic, Pendulum Glucose Control (PGC), can be safely given to patients during pelvic radiation therapy (RT). The researchers will study if the probiotics lessen gastrointestinal toxicity during pelvic radiation.",[33],"2026-02-02",{"date":122,"type":52},"2026-02-05",{"date":124,"type":52},"2026-01-29",{"date":126,"type":21},"2026-12-29",{"name":128,"class":59},"University of Cincinnati",1,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":129},"100583381","the-radiation-protection-for-dose-reduction-in-the-cardiac-catheter-lab-study-the-reduce-trial-100583381","NCT06875583","The Radiation ProtEction for Dose RedUction in the Cardiac CathEter Lab Study: The REDUCE Trial","REDUCE","Inclusion Criteria:\n\n* All procedures involving adult patients (\\>18 year of age)\n* Male or female patients\n* Planned to undergo either an elective or urgent coronary intervention procedure involving ionising radiation in the cardiac catheter lab, via the right and or left radial arteries.\n\nExclusion Criteria:\n\n* Procedures involving patients less than 18 years of age\n* Patients unable to give valid consent\n* Pregnancy\n* Femoral approach procedure",{"count":138,"type":21},100,[72],"Doctors and nurses who perform heart procedures using X-ray guidance are exposed to radiation, which can be harmful over time. This exposure increases the risk of certain health problems, including cancers, eye damage (cataracts), and DNA damage. Although protective lead clothing is used to reduce exposure, it is heavy, uncomfortable, and can cause muscle and joint problems for those who wear it daily.\n\nA new radiation protection device, called RAMPART, may help reduce radiation exposure for heart specialists and their teams. It could also allow them to wear lighter protective gear-or none at all-making their work safer and more comfortable.\n\nThis study will compare the radiation levels received by doctors and nurses during heart procedures when using RAMPART versus standard protection. By doing so, we hope to find out if this new device can better protect medical teams from radiation, improving both their safety and well-being.",[142,143,33,144],"Radiation Exposure","Radiation Exposure to Operator","Radiation Safety",[146,147,148,149],"radiation exposure","radiation exposure to operator","radiation injuries","radiation safety","2025-11-19",{"date":152,"type":52},"2025-11-24",{"date":154,"type":52},"2025-08-29",{"date":156,"type":21},"2026-03-01",{"name":158,"class":59},"Liverpool Heart and Chest Hospital NHS Foundation Trust",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":129},"100541140","clinical-observation-of-drug-retention-enema-in-preventing-acute-radiation-induced-rectal-injury-100541140","NCT06325982","Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury","Clinical Observation of Trolamine Retention Enema in Preventing Acute Radiation-induced Rectal Injury: a Real-world Multicenter Prospective Study","Inclusion Criteria:\n\n* There are clear indications for radiotherapy (pelvic radiotherapy or rectal radiotherapy) according to relevant guidelines;\n* ECOG score 0-1;\n* normal mind, clear consciousness;\n* High compliance;\n* Able to cooperate with the interviewer\n\nExclusion Criteria:\n\n* Poor compliance, unwilling to participate or unable to cooperate with the interviewer;\n* Patients with other intestinal diseases (such as Crohn's disease, rectal ulcer, anal fissure, anal fistula, hemorrhoids, etc.) and perianal diseases;\n* serious heart, brain, liver, kidney disease;\n* Long-term immune dysfunction;\n* Pregnant or lactating women;\n* Patients who terminate treatment for various reasons.",{"count":167,"type":21},200,[72],"The main objective of this study was to evaluate the efficacy and safety of drug retention enema for the prevention of acute radiation rectal injury in the real world.",[33,171],"Rectal Diseases","2024-06-04",{"date":174,"type":52},"2024-06-05",{"date":176,"type":21},"2024-06-11",{"date":178,"type":21},"2025-12-31",{"name":180,"class":181},"Fujian Cancer Hospital","OTHER_GOV"]